At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Jun 11, 2026 at 02:00 ET
Evaxion announced new preclinical data for its off-the-shelf AML vaccine EVX-04, demonstrating complete expression in human cells, immune recognition/activation, and targeted cell-killing across diverse human immune profiles. The data will be presented at EHA 2026 Congress on June 13, 2026, and the company is preparing a regulatory filing for clinical testing. This is positive but early-stage, with no revenue or timeline to clinic.
- EVX-04 is an off-the-shelf therapeutic vaccine for acute myeloid leukemia developed using the AI-Immunology™ platform.
- Preclinical data shows EVX-04 is successfully expressed, secreted in human cells, and induces specific immune responses and targeted cell-killing.
- Data will be presented at the EHA 2026 Congress in Stockholm, Sweden on June 13, 2026.
- The company is preparing a regulatory filing to begin clinical testing, but no timeline for an IND/CTA or first-in-human study was provided.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access